|
gptkbp:instanceOf
|
chemical compound
|
|
gptkbp:analyzes
|
gptkb:Dr._Smith
|
|
gptkbp:campusFacilities
|
gptkb:XYZ_University
|
|
gptkbp:chemicalFormula
|
stable
aromatic ring
aryl amide
C12H15N3O2
|
|
gptkbp:clinicalTrials
|
gptkb:USA
Phase II
promising
|
|
gptkbp:collaborates_with
|
gptkb:ABC_Pharmaceuticals
|
|
gptkbp:collaborations
|
international research team
academic partnership
|
|
gptkbp:community_service
|
overall survival
not identified
|
|
gptkbp:compatibleWith
|
high
|
|
gptkbp:competitors
|
high
|
|
gptkbp:composedOf
|
multi-step synthesis
|
|
gptkbp:contraindication
|
liver toxicity
|
|
gptkbp:dissolved
|
soluble in DMSO
|
|
gptkbp:dosageForm
|
once daily
|
|
gptkbp:drugInterdiction
|
none known
IND-123456
|
|
gptkbp:enrollment
|
ongoing
adults
|
|
gptkbp:evaluates
|
under investigation
|
|
gptkbp:formulation
|
tablet
|
|
gptkbp:funding
|
grants
|
|
gptkbp:future_plans
|
clinical trials
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
WME-1084
|
|
gptkbp:impact
|
fatigue
headache
nausea
favorable
|
|
gptkbp:is_aimed_at
|
cancer
|
|
gptkbp:isATypeOf
|
123456-78-9
|
|
gptkbp:market
|
not marketed
|
|
gptkbp:nutritionalValue
|
liver
|
|
gptkbp:origin
|
N-(4-(4-(dimethylamino)phenyl)-6-methylpyrimidin-2-yl)benzamide
|
|
gptkbp:patentExpiration
|
2030
|
|
gptkbp:patentStatus
|
patented
|
|
gptkbp:publications
|
Journal of Medicinal Chemistry
|
|
gptkbp:regulatoryCompliance
|
pending
|
|
gptkbp:related_to
|
WME-1085
|
|
gptkbp:releaseYear
|
2010
|
|
gptkbp:research_areas
|
oncology
pharmacology
|
|
gptkbp:research_focus
|
targeted therapy
|
|
gptkbp:researchInterest
|
completed
|
|
gptkbp:route
|
oral
|
|
gptkbp:safety_features
|
acceptable
|
|
gptkbp:safetyFeatures
|
ongoing
completed
required
|
|
gptkbp:sponsor
|
gptkb:XYZ_University
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
protein kinase
|
|
gptkbp:triggerType
|
inhibitor of cell proliferation
|
|
gptkbp:uses
|
antitumor agent
|
|
gptkbp:waterManagement
|
urine
|
|
gptkbp:weight
|
233.27 g/mol
|